Overview

Safety/Efficacy Study of Subcutaneously Injected Prandial Insulins Compared to Insulin Lispro Alone in Participants With Type 1 Diabetes Mellitus

Status:
Completed

Trial end date:
2011-08-01

Target enrollment:

Participant gender:

Summary

The purpose of the study is to compare Humalog (Insulin lispro)-recombinant human hyaluronidase (rHuPH20) or Novolog (Insulin aspart)-rHuPH20 to Humalog (Insulin lispro) for the treatment of Type 1 Diabetes Mellitus (T1DM) in basal-bolus therapy.

Phase:

Phase 2

Details

Lead Sponsor:

Halozyme Therapeutics

Treatments:

Insulin
Insulin Aspart
Insulin Glargine
Insulin glulisine
Insulin Lispro
Insulin, Globin Zinc